Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.52 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699709 | 0.85 | ACHE (0.58) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL18974327 | 0.83 | CES1 (0.62) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL281270 | 0.80 | CES1 (0.63) | CES1ALDH1A1CHRM1ALDH2ALDH3A1 | |
| SCHEMBL4597149 | 0.79 | TGM2 (0.61) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL18954691 | 0.78 | TGM2 (0.68) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL1444406 | 0.78 | PRKAG1 (0.67) | ALDH1A1TP53LMNA | |
| SCHEMBL281838 | 0.77 | TRPA1 (0.71) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL18974754 | 0.77 | TGM2 (0.61) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL15928248 | 0.77 | TGM2 (0.75) | TGM2CES1ALDH1A1CHRM1ALDH2 | |
| SCHEMBL27703398 | 0.76 | ALDH1A1 (0.72) | TGM2CES1ALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| EP-2428515-B1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | TGM2 4700/4885CES1 4183/4885ALDH1A1 1136/4885 |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | TGM2 4811/4885CES1 3669/4885ALDH1A1 838/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | TGM2 4811/4885CES1 3669/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.